Neuromuscular blocking agents inhibit receptor-mediated increases in the potassium permeability of intestinal smooth muscle.
The neuromuscular blocking agents tubocurarine, atracurium and pancuronium have been tested for their ability to inhibit receptor-mediated increases in the K+ permeability of intestinal smooth muscle. All three agents, as well as the bee venom peptide apamin, reduced both the resting efflux of 86Rb and the increase in efflux caused by the application of either bradykinin (1 microM) or an alpha 1-adrenoceptor agonist, amidephrine (20 microM), to depolarized strips of guinea-pig taenia caeci. This suggested that like apamin, the neuromuscular blocking agents inhibit the Ca2+-dependent K+ permeability (PK(Ca] mechanism which in this tissue is activated by a variety of membrane receptors. The concentrations (IC50S) of atracurium, pancuronium and (+)-tubocurarine which reduced the effect of amidephrine on 86Rb efflux by 50% were 12, 37 and 67 microM respectively. Also in keeping with an ability to block PK(Ca), the neuromuscular blockers and apamin reduced the inhibition by amidephrine and bradykinin of physalaemin-mediated contractions of the taenia caeci. The IC50 values were 15, 31 and 120 microM for atracurium, tubocurarine and pancuronium respectively, and 2.3 nM for apamin. Each of the neuromuscular blockers, and apamin, increased the spontaneous contractions of the rabbit duodenum and blocked the inhibitory effect of amidephrine thereon. It is concluded that the PK(Ca) mechanism in the longitudinal smooth muscle of the intestine It is concluded that the PK(Ca) mechanism in the longitudinal smooth muscle of the intestine resembles that of hepatocytes and sympathetic ganglion cells in its susceptibility to inhibition by neuromuscular blocking agents, as well as by apamin.
Gater
P R
PR
Haylett
D G
DG
Jenkinson
D H
DH
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000818:Animals; D001030:Apamin / Q000494:pharmacology; D001279:Atracurium; D001920:Bradykinin / Q000494:pharmacology; D002118:Calcium / Q000502:physiology; D002432:Cecum / Q000187:drug effects / Q000502:physiology; D004347:Drug Interactions; D004386:Duodenum / Q000187:drug effects / Q000502:physiology; D004983:Ethanolamines / Q000494:pharmacology; D006168:Guinea Pigs; D066298:In Vitro Techniques; D007546:Isoquinolines / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects* / Q000502:physiology; D009466:Neuromuscular Blocking Agents / Q000494:pharmacology*; D010197:Pancuronium / Q000494:pharmacology; D010803:Physalaemin / Q000494:pharmacology; D011188:Potassium / Q000378:metabolism*; D015221:Potassium Channels; D011817:Rabbits; D017981:Receptors, Neurotransmitter; D014403:Tubocurarine / Q000494:pharmacology
D000316:Adrenergic alpha-Agonists; D004983:Ethanolamines; D007546:Isoquinolines; D009466:Neuromuscular Blocking Agents; D015221:Potassium Channels; D017981:Receptors, Neurotransmitter; C033799:apamin receptor; D001030:Apamin; D010803:Physalaemin; D001279:Atracurium; C016980:amidephrine; D010197:Pancuronium; D011188:Potassium; D001920:Bradykinin; D002118:Calcium; D014403:Tubocurarine